rifapentine and Cushing-Syndrome

rifapentine has been researched along with Cushing-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for rifapentine and Cushing-Syndrome

ArticleYear
Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism.
    Frontiers in endocrinology, 2020, Volume: 11

    Aldosterone-producing adenoma (APA) is a main cause of primary aldosteronism (PA). Given that a large benign-appearing unilateral masse (>1 cm in diameter) may represent an aldosterone and cortisol-co-secreting adenoma, dexamethasone suppression testing is required in such patients to exclude or confirm the diagnosis of hypercortisolism. Tuberculosis is highly prevalent in China, and rifamycins are often used in these patients. Rifapentine belongs to the rifamycin family, and we herein for the first time report a case of misdiagnosis of hypercortisolism due to rifapentine use in a patient with APA. Thus, in patients treated with rifapentine, diagnosis of hypercortisolism based on dexamethasone suppression tests can be very misleading.

    Topics: Cushing Syndrome; Diagnostic Errors; Humans; Hyperaldosteronism; Male; Middle Aged; Pituitary-Adrenal Function Tests; Rifampin

2020